Scoop: A small gene therapy biotech, flush with ex-Sarepta and bluebird leaders, guts CMC

Kyle LaHucik

Senior Reporter

En route to entering the clinic with its first AAV-based gene therapy for a rare neuromuscular disease, AavantiBio has let go of 30 employees, Endpoints News has learned.

The move comes after a year stacking its executive bench with ex-Sarepta and bluebird bio leaders and inking multiple partnerships with the likes of Aldevron, Catalent and Resilience. The biotech also formed a scientific advisory board in February.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Scoop: A small gene therapy biotech, flush with ex-Sarepta and bluebird leaders, guts CMC

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

The Endpoints 100 survey: Has biotech hit rock bottom?

BeiGene builds out long-term case for Brukinsa in CLL, despite an overall survival miss: #ASH23

Bristol Myers’ lead deal negotiator to depart after inking series of multibillion-dollar acquisitions

Early prediction of outcomes in DLBCL clinical trials through MRD testing

Scoop: A small gene ther­a­py biotech, flush with ex-Sarep­ta and blue­bird lead­ers, guts CMC

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

The End­points 100 sur­vey: Has biotech hit rock bot­tom?

BeiGene builds out long-term case for Brukin­sa in CLL, de­spite an over­all sur­vival miss: #ASH23

Bris­tol My­ers’ lead deal ne­go­tia­tor to de­part af­ter ink­ing se­ries of multi­bil­lion-dol­lar ac­qui­si­tions

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

Scoop: A small gene therapy biotech, flush with ex-Sarepta and bluebird leaders, guts CMC

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

The Endpoints 100 survey: Has biotech hit rock bottom?

BeiGene builds out long-term case for Brukinsa in CLL, despite an overall survival miss: #ASH23

Bristol Myers’ lead deal negotiator to depart after inking series of multibillion-dollar acquisitions

Early prediction of outcomes in DLBCL clinical trials through MRD testing